

FIG. 1




FIG. 2
(SEQ ID NO: 1: murine Fc-IgG2a with IL2 signal sequence at the N-terminus)




FIG. 3
(SEQ ID NO: 3: human Fc-IgG1 with IL2 signal sequence at the N-terminus)




FIG. 4
(SEQ ID NO: 5: murine Fc-IgG2a with IL2 signal sequence at the N-terminus and hexa-histidine peptide at the C-terminus)




FIG. 5
(SEQ ID NO: 7: human Fc-IgG1 with IL2 signal sequence at the N-terminus and hexa-histidine peptide at the C-terminus)




FIG. 6
(SEQ ID NO: 9: human Fc-IgG1 with IL2 signal sequence at the N-terminus,
two additional cysteines in the hinge region, and hexa-histidine peptide at the C-terminus)




FIG. 7
(SEQ ID NO: 12: murine Fc-IgG2a with IL2 signal sequence at the N-terminus, Asn to Ala substitution, and hexa-histidine peptide at the C-terminus)




FIG. 8
(SEQ ID NO: 14: human Fc-IgG1 with IL2 signal sequence at the N-terminus,
Asn to Ala substitution, and hexa-histidine peptide at the C-terminus)




FIG. 9
Conjugate 1




FIG. 10
Conjugate 2




FIG. 11
Conjugate 3




FIG. 12
Conjugate 4




FIG. 13
Conjugate 5





FIG. 14
Conjugate 6






FIG. 16
H1N1 Neuraminidase IC₅₀ (nM)





FIG. 17
H3N2 Neuraminidase IC₅₀ (nM)








FIG. 19A




FIG. 19B




FIG. 19D




FIG. 19C




FIG. 19E




FIG. 20A










FIG. 20B










FIG. 21D






FIG. 21E








FIG. 22E

H5N1 (A/Vietnam/1203/04)

1.E+00

1.E+03

1.E+06

Tamiflu

Conjugate 6

2x

Viral reduction

FIG. 23

Conjugate 6 vs hlgG1
8 day mouse PK
50 mpk IV




FIG. 24
Mouse Weight






FIG. 25
Mouse Survival








FIG. 28




FIG. 29











FIG. 30













FIG. 33




FIG. 34C




FIG. 34B




FIG. 34A




FIG. 34D




FIG. 35
Mouse Weight




FIG. 36




FIG. 37




FIG. 38




FIG. 39




FIG. 40
Conjugate 6 plasma and lung levels




FIG. 41
Conjugate 6 IV, SC, and IM administration




FIG. 42
Conjugate 8




FIG. 43
Conjugate 6




FIG. 44
Conjugate 6 in vitro mouse plasma




FIG. 45
Conjugate 6 in vitro human plasma




FIG. 46
Conjugate 6 mouse liver microsomal stability




FIG. 47
Conjugate 6 human liver microsomal stability




FIG. 48
Conjugate 6 and Conjugate 12 *in vivo* efficacy




FIG. 49
Conjugate 6 and Conjugate 12 *in vivo* efficacy




FIG. 50
Conjugate 6 and Conjugate 12 *in vitro* Fcγ receptor IIIA binding




FIG. 51
Conjugate 6 and Conjugate 12 *in vitro* Fcγ receptor IIIA binding




FIG. 52
Toxicokinetics on days 1 and 8




FIG. 53
Mean plasma concentrations following 5 mg/kg IV or SC administration





FIG. 54
Conjugate 12






FIG. 56
Conjugate 6 *in vivo* efficacy in immune compromised mice




FIG. 57
Conjugate 6 *in vivo* efficacy in immune compromised mice




FIG. 58
Conjugate 6 dose-dependent viral clearance in lungs




FIG. 59
Conjugate 6 dose-dependent reduction in inflammatory cytokines in lungs




FIG. 60
Pharmacokinetics of Conjugate 6 in BALB/c SCID mice and CD-1 mice
5 mg/kg IV, single dose




FIG. 61
Conjugate 33

SEQ ID NO: 64




FIG. 62A
Influenza A/Puerto Rico/8/1934 (H1N1)




FIG. 62B
Influenza A/Puerto Rico/8/1934 (H1N1)




FIG. 63A




FIG. 63B




FIG. 64A





FIG. 64B






FIG. 66




FIG. 67




FIG. 68

